The FDA has just made it easier for Sweden’s Calliditas to develop Nefecon for a rare kidney disease, accepting a faster readout that should hasten development of the drug.
Oxford Brain Diagnostic’s Dr Steven Chance explains the importance of early detection of dementia for treatment and research, and why new measurements of neurodegeneration are needed.
